Airway Therapeutics is developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.
AT-100 is the novel recombinant human protein rhSP-D – an engineered version of the endogenous protein hSP-D – that reduces inflammation and infection while modulating the immune response to break the cycle of injury and inflammation.
Bronchopulmonary dysplasia is a ventilation and infection-induced respiratory disease with 200,000 very preterm infants at risk in the U.S. and Europe each year. Globally, about 2.5 million very pre-term infants are at-risk annually. BPD creates long-term lung damage that can lead to pro-longed NICU stays, a range of co-morbidities, lifelong chronic consequences and even death.
For members of the scientific/medical and investment communities,
contact us at the link below by filling out our inquiry form.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.